PML–RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-Talk in Acute Promyelocytic Leukemia Cell Differentiation
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PML–RARA was proposed to initiate acute promyelocytic leukemia (APL) through PML–RARA homodimer–triggered repression. Here, we examined the nature of the PML–RARA protein complex and of its DNA targets in APL cells. Using a selection/amplification approach, we demonstrate that PML–RARA targets consist of two AGGTCA elements in an astonishing variety of orientations and spacings, pointing to highly relaxed structural constrains for DNA binding and identifying a major gain of function of this oncogene. PML–RARA-specific response elements were identified, which all conveyed a major transcriptional response to RA only in APL cells. In these cells, we demonstrate that PML–RARA oligomers are complexed to RXR. Directly probing PML–RARA function in APL cells, we found that the differentiation enhancer cyclic AMP (cAMP) boosted transcriptional activation by RA. cAMP also reversed the normal silencing (subordination) of the transactivating function of RXR when bound to RARA or PML–RARA, demonstrating that the alternate rexinoid/cAMP-triggered APL differentiation pathway also activates PML–RARA targets. Finally, cAMP restored both RA-triggered differentiation and PML–RARA transcriptional activation in mutant RA-resistant APL cells. Collectively, our findings directly demonstrate that APL cell differentiation parallels transcriptional activation through PML–RARA-RXR oligomers and that those are functionally targeted by cAMP, identifying this agent as another oncogene-targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 1×
“cAMP greatly enhances expression of the PGC-1 coactivator (44, 45) and recent reports have pointed to dynamic equilibrium between corepressor, coactivators, and RA-bound conformations of RARA (46), which may explain our findings.”
BackgroundThe promise of retinoids to fight against cancer
Altucci, L., & Gronemeyer, H. (2001) · Nature Reviews Cancer · doi:10.1038/35106036 · Cited by 773 · cited 1×
“This pathway could be active in non-APL leukemias and extend the concept of differentiation therapy to other hematological malignancies (21).”
BackgroundGiannì, M., Bauer, A., Garattini, E., Chambon, P., & Rochette‐Egly, C. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf374 · Cited by 151 · cited 1×
“DNA binding has been implicated in RARs degradation (15, 37), possibly through a shift in RAR– RXR conformation, which may not occur in the context of oligomers.”
BackgroundTaneja, R., Rochette‐Egly, C., Plassat, J., Penna, L., Gaub, M., & Chambon, P. (1997) · The EMBO Journal · doi:10.1093/emboj/16.21.6452 · Cited by 113
Cited by
RAR and RXR modulation in cancer and metabolic disease
Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R., & Gronemeyer, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2397 · Cited by 517
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure
de Thé, H., & Chen, Z. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2943 · Cited by 488
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
Nasr, R., Guillemin, M.-C., Ferhi, O., Soilihi, H., Peres, L., Berthier, C., Rousselot, P., Robledo-Sarmiento, M., Lallemand-Breitenbach, V., Gourmel, B., et al. (2008) · Nature Medicine · doi:10.1038/nm.1891 · Cited by 354
Self-citationPML-RARα/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia
Martens, J. H. A., Brinkman, A. B., Simmer, F., Francoijs, K.-J., Nebbioso, A., Ferrara, F., Altucci, L., & Stunnenberg, H. G. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.042 · Cited by 292
Guibal, F. C., Alberich-Jorda, M., Hirai, H., Ebralidze, A., Levantini, E., Di Ruscio, A., Zhang, P., Santana-Lemos, B. A., Neuberg, D., Wagers, A. J., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182071 · Cited by 126
P38MAPK‐dependent phosphorylation and degradation of SRC‐3/AIB1 and RARα‐mediated transcription
Giannì, M., Parrella, E., Raska, I., Gaillard, E., Nigro, E. A., Gaudon, C., Garattini, E., & Rochette‐Egly, C. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600981 · Cited by 81
Gaillard, E., Bruck, N., Brelivet, Y., Bour, G., Lalevée, S., Bauer, A., Poch, O., Moras, D., & Rochette-Egly, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509717103 · Cited by 76
Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells
Racanicchi, S., Maccherani, C., Liberatore, C., Billi, M., Gelmetti, V., Panigada, M., Rizzo, G., Nervi, C., & Grignani, F. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600593 · Cited by 36
Cell hierarchy, metabolic flexibility and systems approaches to cancer treatment
M. Herst, P., & V. Berridge, M. (2013) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201011314030005 · Cited by 16
Metadata
- Authors
- Kamashev, D., Vitoux, D., & de Thé, H.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2004-04-19
- Volume
- 199
- Issue
- 8
- Pages
- 1163-1174
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2147567567
- Cited by
- 153
- References
- 4
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.